Systematic identification of the mechanistic evidence for cancer hazard assessment: Experience of the IARC Monographs programme

> Kate Z. Guyton PhD DABT Senior Toxicologist Responsible Officer, Volume 112 Monographs Programme

International Agency for Research on Cancer Lyon, France

Conflict of Interest Statement

I declare no financial interests related to the subject matter of my presentation.



Presentation Overview

- IARC Monograph- background
- Challenges and recommendations for mechanistic data
- Recent experience in search and organisation of mechanistic information
 - o Published literature
 - o Tox21 data
- Summary



"The Encyclopaedia of Carcinogens"

Agents are recommended by international advisors based on:


- Evidence of human exposure
- Some evidence or suspicion of carcinogenicity

More than 980 agents have been evaluated

- > 118 are *carcinogenic to humans* (Group 1)
- 75 are probably carcinogenic to humans (Group 2A)
- 287 are possibly carcinogenic to humans (Group 2B)
- 503 are not classifiable as to its carcinogenicity to humans (Group 3)
- 1 is classified as *probably not carcinogenic to humans* (Group 4)

National and international health agencies use the Monographs


- To identify carcinogens
- To prevent exposure to known or suspected carcinogens





orenzo Iomatis 1929-2007


How Are IARC Monograph Evaluations Conducted?



Organization

- Procedural guidelines for participant selection, conflict of interest, stakeholder involvement & meeting conduct
- Separate criteria for review of human, animal and mechanistic evidence
- Decision process for overall evaluations

http://monographs.iarc.fr/ENG/Preamble/index.php




"Systematic approach to cancer hazard evaluation":

International Agency for Research on Cancer \circ Systematic gathering and review of all lines of evidence

o Uniform, hierarchic evaluation structure




The IARC Monographs Evaluations: *A Two-Step Process*



Mechanistic Data Are Pivotal When Human Data Are Not Sufficient (Example 1)

EVIDENCE IN EXPERIMENTAL ANIMALS




Strong supporting evidence in exposed humans



International Agency f

Mechanistic Data Are Pivotal When Human Data Are Not Sufficient (Example 2)

EVIDENCE IN EXPERIMENTAL ANIMALS



Mechanistic Data Are Pivotal When Human Data Are Not Sufficient (Example 3)

EVIDENCE IN EXPERIMENTAL ANIMALS

		Sufficient	Limited Inadequate					
EVIDENCE IN HUMANS	Sufficient	Group 1 (carcinogenic to humans)						
	Limited	Group 2A (probably carcinogenic)	Group 2B <i>(possibly carcinogenic)</i> (exceptionally, Group 2A)					
	Inadequate	Group 2B (possibly carcinogenic)	Group 3 (not classifiable)					
rnational Agency for Researc World Health Organization		Strong evidence: mechanism in animals DOES NOT operate in humans						

Internat

Insights from Volume 100 and Advisory Groups






- The volume and complexity of mechanistic evidence is increasing
- Analysis of high-throughput/-content data (including from curated government databases) is encouraged
- Objective methods to identify, select and evaluate mechanistic evidence are needed
- Although not necessarily representing mechanisms themselves, the key characteristics of human carcinogens can be used to advance systematic evaluation of relevant mechanistic data

Mechanistic Studies: Looking Forward





ranization

Considerations:

- 1. Monographs cite hundreds-thousands of studies
- 2. Evolution in experience over time:
 - Mail box(es) of papers (1970s-1980s era)
 - Electronic reference list, PDFs, database (1990s)
 - Sorted list of references by subject (early 2000s)

Challenges:

- 1. How, when, where were searches done?
- 2. Which studies were included/excluded?
- 3. So many mechanisms, so little time:
 - How to search systematically for relevant mechanisms?
 - How to bring uniformity across assessments (strength- but also lack of availability- of data)?
 - How to analyze the voluminous mechanistic database efficiently?

Strategy

- 1. Identify studies through documented searches
- 2. Organise the inventory of studies/data
- 3. Increase clarity in evidence summary and evaluations:
 - How much evidence? ("no evidence" vs "weak/moderate/strong")
 - For what effects (which key characteristics)
 - In what tests (humans, in vitro, etc)





Step 1: Identify Studies through Well-Documented Searches

Information Sources:

- 1. Literature
 - Targeted literature searches on each key characteristic to address specific hypotheses
 - "Hand searching" for additional literature
 - o General literature searches on the agent
 - Authoritative reviews (e.g., past Monographs)
 - o Public submissions to "call for data"
 - o Working Group
- 2. <u>Publicly available data (e.g., ToxCast, Tox21,</u> ToxRefDB, *etc*)



Step 1: Identify Studies through Well-Documented Searches

- Search for literature on each key characteristic
 - Terms developed with IARC, librarian, expert input
 - Expected to evolve over time (experience and MeSH tagging)
 - Mix of MeSH and text terms (facilitates updating before meeting)
- Complemented by "hand searching"
- Document searches and results using HΔWC online tool (HAWCproject.org)
 B Genotoxic
 Description
 Clyphosate and AMPA

De

Se

Description	Glyphosate and AMPA		
Search Type	Search		
Search Database PubMed			
Search Text	("glyphosate"[Supplementary Concept] OR "glyphosate"[All Fields]) OR ("aminomethylphosphonic acid" [Supplementary Concept] OR "aminomethylphosphonic acid"[All Fields]) AND ("Mutation"[Mesh] OR "Cytogenetic Analysis"[Mesh] OR "Mutagens"[Mesh] OR "Oncogenes"[Mesh] OR "Genetic Processes"[Mesh] OR "genomic instability"[Mesh] OR chromosom* OR clastogen* OR "genetic toxicology" OR "strand break" OR "unscheduled DNA synthesis" OR "DNA damage" OB "DNA adducts" OR "SCE" OB "chromatid" OB mutagens"		

OR "DNA repair" OR "UDS" OR "DNA fragmentation" OR "DNA cleavage")

Induces Epigenetic Alterations

Description	Glyphosate and AMPA
Search Type	Search
Search Database	PubMed
Search Text	("aminomethylphosphonic acid"[Supplementary Concept] OR "aminomethylphosphonic acid"[All Fields] OR "glyphosate"[Supplementary Concept] OR "glyphosate"[All Fields]) AND ("rna"[MeSH Terms] OR "rna"[All Fields] OR "rna, messenger"[MeSH Terms] OR "rna"[All Fields] OR "messenger rna"[All Fields] OR "mrna"[All Fields] OR "histones"[MeSH Terms] OR "histones"[All Fields] OR "epigenetic"[All Fields] OR "miRNA"[All Fields] OR "methylation"[All Fields])

Induces Oxidative Stress

International Agency for Research on Cance



nce	Description	Oxidative stress
	Search Type	Search
	Search Database	PubMed
	Search Text	("glyphosate"[Supplementary Concept] OR "glyphosate"[All Fields]) OR ("aminomethylphosphonic acid" [Supplementary Concept] OR "aminomethylphosphonic acid"[All Fields]) AND ("reactive oxygen species"[MeSH] OR "reactive nitrogen species"[MeSH] OR "reactive oxygen species" OR "oxygen radicals" OR "oxidative stress" [MeSH] OR oxidative OR "oxidative stress" OR "free radicals")



Actions -

Actions

Actions

Step 2: Develop an Organized Inventory of Studies/Data

IARC Vol 112- Mono 4- Glyphosate (2015): Literature Tagtree

0 Non-human primates

(2)


Organizing Principles:

- **Topic (key characteristics)**
- **Species**

Utility

- Document exclusions
- **Develop outline**

HEALTH ASSESSMENT



Step 2: Develop an Organized Inventory of Studies/Data

16/12/15 11:21

Key characteristics- endpoints and assays - Google Sheets

guytonk@iarc.fr 👻 Key characteristics- endpoints and assays ☆ 顧 Share Comments File Edit View Insert Format Data Tools Add-ons Help Last edit was made on January 5 by Matthew Martin (des)(d No. 00000 (Real) No. 123 \$ % Arial 10 No. А в С D Е F G н Related characteristic 1 (if any) for **Compendium of** Characteristic Endpoint Assays endpoint-assay 1- Electrophilicity or ability to Electrophilic structure endpoints and assays 2 undergo metabolic activation (e.g., expoxide, guinone) 3 Protein adduction Hemoglobin adducts associated with each Key 4 2- Genotoxic DNA damage DNA adducts Characteristic 5 DNA strand breaks DNA array 6 • **Developed by** 7 DNA oxidation 5 IARC and experts 8 Unsurvey 9 Intercalation • Expected to evolve 10 SOS repair test Poly(ADP-ribose)polymerase over time 11 induction (PADPR) 12 13 Mutation Mouse spot test 14 Mouse specific locus test 15 Dominant lethal test Oncogene/tumor suppressor 16 gene mutation 17 Tk, Hprt, other gene mutation Ouabain resistance 18 19 Reverse mutation

Step 2: Develop an Organized Inventory of Studies/Data

10 Key characeristic of human carcinogens:

1. Electrophilic or ability to undergo metabolic activation

3. Alters DNA repair or causes genomic instability

ToxCast iCSS dashboard

(http://actor.epa.gov/dashboard/)

• 821 assays

1860 chemicals



4. Epigenetic Alterations

2. Genotoxic

- 5. Oxidative Stressor
- 6. Induces chronic inflammation
- 7. Immunosuppressant
- 8. Modulates receptor-mediated effects
- 9. Immortalization


10. Alters cell proliferation, cell death, or nutrient supply

??

At most, 274 ToxCast/Tox21 assays could be mapped to a "key characteristic":

Key characteristic	1. Electrophilic or ability to undergo metabolic activation	2. Genotoxic	4. Causes Epigenetic alterations	5. Oxidative stressor	6. Induces chronic inflammation	8. Modulat recepto mediated e	r- proliferation, cell
Assay Endpoints	31 assays: •CYP inhibition (29) •Aromatase inhib. (2)	[9 assays: •p53 activation]	11 assays:DNA binding (4)Transformation (7)	18 assays: • Metalloproteinase (5) • Oxidative stress (7) • Oxidative stress marker (6)	45 assays: • Cell adhesion (14) • Cytokines (29) • NFkB (2)	81 assays •AhR (2) •Othe •AR (11) •PPAR •ER (18) •PXR_ •FXR (7) •RAR (rs (18) • Cell cycle (16) (12) • Cytotoxicity (41) VDR (7) • Mitochondrial
No assay coverage for these "key characteristics" 3. Alters DNA repair or causes genomic instability 7. Immunosuppressant 9. Immortalization							

Step 3: Summarize Mechanistic Evidence by Key Characteristic



Key	8. Modulates receptor-mediated		
characteristic	events		
Sub- characteristics	92 assays: AhR(2); AR(11); ER(18); FXR(7); Others (18); PPAR(12); PXR/VDR(7); RAR(6)		

Volume 112 (Diazinon):

Diazinon demonstrated activity in both assays for AhR, and in a subset of estrogen receptor alpha and beta assay endpoints. Diazoxon exhibited little activity (may be attributable to high reactivity and short half-life)

Step 3: Summarize Mechanistic Evidence by Key Characteristic

Example: Glyphosate summary

Characteristic	Strength of evidence for glyphosate	Does this– or can it– operative in humans?
1. Is Electrophilic or Can Be Metabolically Activated	Not electrophilic	
2. Is Genotoxic	Strong	Can operate in humans
3. Alters DNA Repair or Causes Genomic Instability	No data	
4. Induces Epigenetic Alterations	No data	
5. Induces Oxidative Stress	Strong	Can operate in humans
6. Induces Chronic Inflammation	No data	
7. Is Immunosuppressive	Weak	
8. Modulates Receptor- mediated Effects	Weak	
9. Causes Immortalization	No data	
10. Alters Cell Proliferation, Cell Death or Nutrient	Weak	

supply

".. Strong evidence that glyphosate can operate through two key characteristics of known human carcinogens, and that these can be operative in humans"

http://monographs.iarc.fr/ENG/Monographs/vol112/mono112-09.pdf

Summary of Mechanistic Evidence in Recent IARC Monographs Evaluations

Agent	Human evidence	Animal evidence	Mechanistic evidence	Group
Diazinon	Limited (NHL, leukemia, lung)	Limited	Genotoxicity, oxidative stress	2A
Glyphosate	Limited (NHL)	Sufficient	Genotoxicity, oxidative stress	2A
Malathion	Limited (NHL, prostate)	Sufficient	Genotoxicity, oxidative stress, inflammation, receptor-mediated effects, and cell proliferation or death	2A
Parathion	Inadequate	Sufficient		2B
TCVP	Inadequate	Sufficient		2B
Lindane	Sufficient (NHL)	Sufficient	Immunosuppression	1
DDT	Limited (NHL, liver, testis)	Sufficient	Immunosuppression, oxidative stress, receptor-	2A
	, ,		mediated effects	

IARC Monographs: Example Timeline

IARC Secretariat: Coordinate all aspects of the Monograph development Write the reviews and evaluat	ng Have cri mbers: but als critical develop [do no ons pa	d Specialists: tical knowledge to a conflicting interest of draft text or rticipate in aluations]	Representati national ar international h agencies [do not draft t participate evaluation	nd Allow nealth but n rext or [do n p in po	bservers: wed to observe ot to influence outcomes ot draft text or articipate in valuations]	
 IARC Secretariat: Identify studies through well- documented searches Organize inventory of studies/data Recruit Working Group, organize and conduct meeting per published procedures 	 Perform suppl Evaluate studi Add comment 	 Working Group members: Perform supplemental literature searches Evaluate studies against published criteria Add comments [in square brackets] Draft assigned sections Peer-review 			Monograph in-person meeting: •Evidence summary and evaluation •Plenary review and overall evaluation	
Meeting announced (March 2014):			The Lancet	References		
 Preliminary List of Agents Call for Data and Experts Request for Observer Status WHO Col form posted 		List of Participants announced (Jan. 2015)	Oncology publication (March 2015)	shared with health agencies (April 2015)	Glyphosate Monograph publication (July 2015)	

Summary: IARC Monographs

- Scientific findings providing insights into cancer mechanisms play an essential role in carcinogen hazard identification
- The key characteristics of known human carcinogens provide the basis for an objective, systematic approach for identifying and evaluating mechanistic data
- Recent IARC Monographs evaluations have illustrated the applicability of this approach
- These developments lay groundwork for future evaluations where such data may fill important gaps in evidence of carcinogenicity and and a such as a such asuch as a such as a

World Healt Organizatio

Acknowledgments

US EPA Organizers The IARC Monographs Volume 100+, 112 & 113 Working Groups MT Smith and all co-authors Andy Shapiro (NIEHS/NTP) The IARC Monographs Staff







Thank YOU- and happy holidays!

International Agency for Research on Cancer THE FIRST 50 YEARS, 1965 – 2015

NOW AVAILABLE







